The effect of combined treatment to reduce body dysmorphic disorder in wome
Phase 2
- Conditions
- F45.22Body dysmorphic disorder.Body dysmorphic disorder
- Registration Number
- IRCT20220730055583N1
- Lead Sponsor
- Vice President of Research and Technology of Ferdowsi University of Mashhad Ferdowsi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 3
Inclusion Criteria
Being women
Body dysmorphic disorder
Age between 20 and 50 years old
Exclusion Criteria
Intellectual disability
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Body deformity disorder. Timepoint: At the beginning of the study and 3, 6, 9, 13 and 16 weeks after the start of the treatment. Method of measurement: content analysis.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie body dysmorphic disorder (F45.22) in women and how can they be targeted for treatment?
How does the intervention in IRCT20220730055583N1 compare to standard-of-care treatments for F45.22 in terms of efficacy and safety?
Are there specific biomarkers that can predict treatment response in women with body dysmorphic disorder (F45.22) for this trial?
What are the potential adverse events associated with the treatment model in IRCT20220730055583N1 and how can they be managed?
What combination therapies or related compounds are being explored for body dysmorphic disorder (F45.22) alongside this trial's approach?